

## **Correction: A randomized, phase II study of gefitinib alone versus nimotuzumab plus gefitinib after platinum-based chemotherapy in advanced non-small cell lung cancer (KCSG LU12-01)**

**Hye Ryun Kim, Joung Soon Jang, Jong-Mu Sun, Myung-Ju Ahn, Dong-Wan Kim, Inkyung Jung, Ki Hyeong Lee, Joo-Hang Kim, Dae Ho Lee, Sang-We Kim and Byoung Chul Cho**

Copyright: Kim et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License 3.0 (CC BY 3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

**Present:** The current funding information is incomplete.

**Correct:** The complete funding information is given below.

Original article: Oncotarget. 2017; 8:15943-15951. <https://doi.org/10.18632/oncotarget.13056>

### **FUNDING**

This study was supported partly by Astra Zeneca Korea Ltd. This study was supported in part by a grant from the Korea Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI12C1440, B. C. Cho), a grant from the Korean Health Technology R&D Project, Ministry of Health & Welfare, Republic of Korea (HI13C1948 to H.R. Kim) and a faculty research grant of Yonsei University College of Medicine for 2012(6-2012-0134, B.C. Cho.).